Article

Optimization and validation of a high performance liquid chromatography method for rapid determination of sinafloxacin, a novel fluoroquinolone in rat plasma using a fused-core C(18)-silica column.

Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, PR China.
Journal of pharmaceutical and biomedical analysis (Impact Factor: 2.45). 10/2009; 51(4):889-93. DOI: 10.1016/j.jpba.2009.09.046
Source: PubMed

ABSTRACT A novel, simple and rapid high performance liquid chromatographic method has been developed and validated for the determination of sinafloxacin, a new fluoroquinolone, in rat plasma using 96-well protein precipitation, fused-core C(18)-silica column (4.6mmx50mm, 2.7microm) packed with a new solid support, which is made of 2.7microm particles that consist of a 1.7microm solid core covered with a 0.5microm thick shell of porous silica.The chromatographic separation was achieved with a mobile phase of 20:80 (v/v) of acetonitrile and phosphate buffer (pH=3.0) at a flow rate of 1mlmin(-1). Fluorescence detection was employed with lambda(ex) 295nm and lambda(em) 505nm. Lomefloxacin was used as internal standard (IS). The total analysis time was as short as 3min. The method was sensitive with a limit of detection (LOD) of 2ngml(-1), with good linearity (R(2)=0.9996) over the linear range of 5-500ngml(-1). The intra-day and inter-day precision was less than 5.8% and accuracy ranged from 100.3% to 103.5% for quality control (QC) samples at three concentrations of 10, 50 and 400ngml(-1).The fused-core C(18)-silica column method offered high sample throughput, low injection volume and low consumption of organic solvents. The method was successfully employed in the pharmacokinetic study of sinafloxacin formulation product after tail vein injection to healthy rats.

0 Bookmarks
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple and rapid method for the determination of residues of four fluoroquinolones in blood samples was developed. The method was based on matrix solid-phase dispersion extraction followed by CE with ultraviolet detection. 1-Butyl-3-methylimidazolium tetrafluoroborate aqueous solution was used as the background electrolyte for the separation of fluoroquinolones. The average recoveries of the four fluoroquinolones at two spiked levels ranged from 54.0 to 86.4% for pig blood, and 45.4 to 79.9% for deer blood, with the relative standard deviations <9.45%. Detection limits for the four fluoroquinolones in blood sample ranged from 0.15 to 0.31 μg/mL.
    Journal of Separation Science 03/2011; 34(7):822-9. · 2.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For the first time, a fast, high-performance liquid chromatography (HPLC) method was developed and validated for the simultaneous determination of the new ultra-short hypnotic HIE-124 and its metabolite in mice serum. Each compound, together with carbamazepine (internal standard) was extracted from the serum matrix using liquid-liquid extraction (LLE). Chromatographic resolution of the analytes was performed on a Chromolith Speed Rod monolithic silica column (100 mm × 4.6 mm i.d.) under isocratic conditions using a mobile phase of 65:35 (v/v), 20 mM phosphate buffer (pH 7.0 adjusted with phosphoric acid)-acetonitrile. The elution of the analytes were monitored at 240 nm and conducted at ambient temperature. Because of high column efficiency the mobile phase was pumped at a flow rate of 2.5 mL min(-1). The total run time of the assay was 2 min. The method was validated over the range of 60-2000 ng mL(-1) for HIE-124 and 200-1600 ng mL(-1) for the metabolite (r(2) = 0.99). The limit of detection (LOD) for HIE-124 and its metabolite were 20 ng mL(-1) and 65 ng mL(-1), respectively. The proposed method was validated in compliance with ICH guidelines, in terms of accuracy, precision, limits of detection and quantitation and other aspects of analytical validation. The developed method could be used for the trace analyses of HIE-124 and its metabolite in serum and was finally used for the pharmacokinetic study investigation of HIE-124 in mice serum.
    The Analyst 11/2010; 136(3):591-7. · 4.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present work describes the systematic development of a robust, precise and rapid reversed-phase liquid chromatography method for the simultaneous determination of eprosartan mesylate and its six impurities using Quality by Design principles. The method was developed in two phases; screening and optimization. During screening phase, the most suitable stationary phase, organic modifier and pH were identified. The optimization was performed for secondary influential parameters; column temperature, gradient time and flow rate using eight experiments to examine multifactorial effects of parameters on the critical resolution and generated design space representing the robust region. A verification experiment was performed within working design space and model was found to be accurate. This study also describes other operating features of column packed with superficially porous particles that allows very fast separations at pressures available in most liquid chromatography instruments. Successful chromatographic separation was achieved in less than 7 min using a fused-core C18 (100 mm × 2.1 mm, 2.6 μm) column with linear gradient elution of 10 mM ammonium formate (pH 3.0) and acetonitrile as the mobile phase. The method was validated for specificity, linearity, accuracy, precision and robustness in compliance to the ICH Q2 (R1) guidelines. The impurities were identified by liquid chromatography with mass spectrometry. This article is protected by copyright. All rights reserved.
    Journal of Separation Science 06/2014; · 2.59 Impact Factor